← All trials
NCT05576454
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 20, 2022
- Primary completion
- Feb 28, 2023
- Completion date
- Jun 30, 2023
- First posted
- Oct 12, 2022
- Last posted
- Oct 12, 2022
- Enrollment
- 207
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- BiotheraLead sponsor
- Jinlin UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.